Search strategy
This meta-analysis was undertaken according to the Preferred Reporting
Items of Systematic Reviews and Meta-Analysis (PRISMA) statement
guideline [11] and Cochrane handbook for systematic reviews of
interventions[12]. Two independent authors systematically searched
literature in online medical search engines including PubMed/Medline,
Scopus and Google Scholar were searched for relevant articles published
from inception until May 2020. Combination of both following MESH and
non-MESH terms were used: (orlistat[MeSH Terms] OR
Tetrahydrolipstatin[MeSH Terms] OR THLP[MeSH Terms] OR
Tetrahydrolipastatin[MeSH Terms] OR Alli[MeSH Terms] OR
Xenical[MeSH Terms] OR Roche brand of orlistat[Title/Abstract])
OR Hoffmann‐La Roche brand of orlistat[Title/Abstract]) AND (Uric
acid[MeSH Terms] OR Acid, Uric[MeSH Terms] OR
2,6,8-Trihydroxypurine[MeSH Terms] OR Trioxopurine[MeSH Terms]
OR Urate[MeSH Terms] OR Blood uric acid[Title/Abstract] OR
Hyperuricemia[Title/Abstract] OR HU[Title/Abstract] OR Serum
uric acid[Title/Abstract] OR SUA[Title/Abstract] OR High serum
uric acid [Title/Abstract] OR HSUA level[Title/Abstract] OR
UA[Title/Abstract]). The search was also completed by manual search
of the references list of clinical trials and previous review articles
to include other potentially eligible trials. Language
restrictions (English) were applied in our search strategy. The PubMed’s
e-mail alert service was also activated to find any new articles that
might appear in this area after our primary search.